Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4GTS

Engineered RabGGTase in complex with BMS analogue 16

Summary for 4GTS
Entry DOI10.2210/pdb4gts/pdb
Related4GTM 4GTO 4GTP 4GTQ 4GTR 4GTT 4GTV
DescriptorGeranylgeranyl transferase type-2 subunit alpha, Geranylgeranyl transferase type-2 subunit beta, ZINC ION, ... (6 entities in total)
Functional Keywordsprotein prenylation, inhibitor, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceRattus norvegicus (rat)
More
Total number of polymer chains2
Total formula weight75782.60
Authors
Guo, Z.,Stigter, E.A.,Bon, R.S.,Waldmann, H.,Blankenfeldt, W.,Goody, R.S. (deposition date: 2012-08-29, release date: 2012-10-24, Last modification date: 2023-11-08)
Primary citationStigter, E.A.,Guo, Z.,Bon, R.S.,Wu, Y.W.,Choidas, A.,Wolf, A.,Menninger, S.,Waldmann, H.,Blankenfeldt, W.,Goody, R.S.
Development of Selective, Potent RabGGTase Inhibitors
J.Med.Chem., 55:8330-8340, 2012
Cited by
PubMed Abstract: Members of the Ras superfamily of small GTPases are frequently mutated in cancer. Therefore, inhibitors have been developed to address the acitivity of these GTPases by inhibiting their prenylating enzymes FTase, GGTase I, and RabGGTase. In contrast to FTase and GGTase I, only a handful of RabGGTase inhibitors have been developed. The most active RabGGTase inhibitor known until recently was an FTase inhibitor which hit RabGGTase as an off-target. We recently reported our efforts to tune the selectivity of these inhibitors toward RabGGTase. Here we describe an extended set of selective inhibitors. The requirements for selective RabGGTase inhibitors are described in detail, guided by multiple crystal structures. In order to relate in vitro and cellular activity, a high-throughput assay system to detect the attachment of [(3)H]geranylgeranyl groups to Rab was used. Selective RabGGTase inhibition allows the establishment of novel drug discovery programs aimed at the development of anticancer therapeutics.
PubMed: 22963166
DOI: 10.1021/jm300624s
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.45 Å)
Structure validation

226707

PDB entries from 2024-10-30

PDB statisticsPDBj update infoContact PDBjnumon